SmiLe companies selected for NLSDays “Startup Challenge” pitch competition

NLSDays, the largest Nordic partnering conference dedicated to the life sciences, is being held in Stockholm this year. Two companies from SmiLe Incubator in Lund, Akuru Pharma and Gedea Biotech, will compete before a Nordic jury in the NLSDays pitch competition this evening. They were selected following tough competition with other Nordic startup companies.

 

Akuru Pharma and Gedea Biotech made it to the pitch final based on their video descriptions of their companies. The 12 best companies get to enter the competition and pitch their innovations and business plans on-site in Stockholm. They will do so before a knowledgeable audience that will include both investors and representatives from the life science industry.

 

“Having many opportunities to expose their startup companies is important for our entrepreneurs, both for meeting national and international contacts in the industry and for fine-tuning the description of their specific business opportunities. We are pleased that companies from SmiLe Incubator have once again been chosen for the competition,” says Ebba Fåhraeus, CEO of SmiLe Incubator of Lund.

 

The following Nordic startup companies in fields such as pharmaceuticals, medtech, diagnostics and e-health will compete in the “Startup Challenge @ NLSDays 2018” this evening at 6 p.m.: Akuru Pharma, Bioreperia, Game Intelligence, Gedea Biotech, Letsip, Lipum, MediTuner, Operationskollen, Quantum Leap Computing Labs. Sigrid Therapeutics, Stayble Therapeutics, Tirmed Pharma.

 

About Akuru Pharma: Akuru Pharma is a biomedical company focused on developing novel diagnostic and treatment modalities for conditions such as kidney cancer, based on research from Lund University.

Contact: CEO Jennifer Hansson, +46 (0)702-145673,  www.akurupharma.com

 

About Gedea Biotech: Gedea Biotech is developing a new treatment method for vaginal infections. Vaginal infections can be caused by both bacteria and fungi and Gedea’s treatment is expected to be highly efficacious for treating both conditions. In the fall of 2018 the first clinical study will be conducted using GDA001 in patients with vaginal fungal infections.
Contact: Annette Säfholm, CEO, +46 (0)708-918681, www.gedeabiotech.com

 

About Startup Challenge @ NLSDays 2018: https://www.nlsdays.com/program/startup-challenge/

For information about SmiLe Incubator, contact: Ebba Fåhraeus, CEO at SmiLe Incubator
+46 (0)734000433, ebba@smileincubator.life ; Or visit our mediaroom

---

---